Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $42.6 million.

  • Capricor Therapeutics' Total Liabilities rose 7244.52% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 7244.52%. This contributed to the annual value of $25.0 million for FY2024, which is 3075.9% down from last year.
  • Capricor Therapeutics' Total Liabilities amounted to $42.6 million in Q3 2025, which was up 7244.52% from $28.6 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Total Liabilities registered a high of $47.7 million during Q1 2023, and its lowest value of $6.4 million during Q3 2021.
  • For the 5-year period, Capricor Therapeutics' Total Liabilities averaged around $29.3 million, with its median value being $31.0 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 50493.84% in 2022, then plummeted by 3813.51% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Total Liabilities (Quarter) stood at $10.0 million in 2021, then soared by 284.54% to $38.3 million in 2022, then fell by 5.68% to $36.1 million in 2023, then plummeted by 30.76% to $25.0 million in 2024, then skyrocketed by 70.16% to $42.6 million in 2025.
  • Its Total Liabilities stands at $42.6 million for Q3 2025, versus $28.6 million for Q2 2025 and $26.1 million for Q1 2025.